FGF9 ELISA Kit (Fibroblast Growth Factor-9)

INTENDED USE

Human FGF9 ELISA kit is a reliable quantitative procedure for measuring fibroblast growth factor-9 (FGF-9, FGF9) in human serum, plasma, biological fluids and tissue homogenates. This assay has a minimum sensitivity detection limit of 37.5 pg/ml.

BACKGROUND

Fibroblast growth factor-9 (FGF9, FGF-9) is involved in biological processes such as; cell growth, morphogenesis, tissue repair, invasion, embryonic development and tumor growth. The cDNA has been cloned using oligonucleotide probes that encode a polypeptide consisting of 208 amino acids and it share approx. 30% sequence similarity to the other FGF-family members.

FGF9 is produced and secreted by the prostatic stromal cells, it is a survival factor for mesenchymal or nerve cells and a potent mitogen activator for both prostatic stromal or epithelial cells in culture. It is a growth factor that is abundantly secreted and can act as either an autocrine mitogen for stromal cells or a paracrine mitogen for epithelial cells.

The standard that is used in this assay is a recombinant anti human FGF9 that is made up of 208 amino acids and has a molecular mass of 23KDa, due to glycosylation, the molecular mass can be between 25-27KDa.

CONTENT

All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

• One 96-Well Plate: Pre-coated with anti FGF-9 antibody.
• Standards: Concentrations 0, 62.5, 125, 250, 500, 1000, 2000, 4000 pg/ml.
• Sample/Standard Dilution Buffer.
• Biotinylated-Labelled-Antibody.
• Antibody Dilution Buffer.
• HRP-Streptavidin Conjugate (SABC).
• SABC Dilution Buffer.
• TMB Substrate.
• Wash Buffer (25x).
• Plate Sealer.
• Product Instructions.

SENSITIVITY

The minimum sensitivity detection limit of fibroblast growth factor-9 (FGF-9, FGF9) using current FGF9 ELISA kit was approximately 37.5 pg/ml. The dynamic range for this assay is 62.5 – 4,000.0 pg/ml.

ASSAY CHARACTERISTICS

– Specificity: Highly specific for FGF9, no cross reactivity or interference between FGF-9 and analogues was detected.
– Recovery: Serum (87 – 103%), EDTA Plasma (85 – 104%), Heparin Plasma (87 – 100%).
– Linearity: Serum (85 – 105%), EDTA Plasma (82 – 100%), Heparin Plasma (80 – 99%).
– Precison Intra-Assay: CV < 8%.
– Precison Inter-Assay: CV < 10%.
– Stability: Less than 10%.

REFERENCES

1. FGF9 on the move. Nat Genet. (2009) 41 (3): 272-3. Spicer D.
2. Accumulation of FGF-9 in prostate cancer correlates with epithelial-to-mesenchymal transition and induction of VEGF-A expression. Anticancer Res. (2014) 34 (2): 695-700. Teishima J., et al.
3. Autoinhibitory mechanism for the mutation-induced impaired FGF9 signaling. J Chem Inf Model. (2012) 52 (9): 2422-9. Wang Y., et al.
4. FGF-9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol. (1999) 180 (1): 53-60. Giri D., Ropiquet F. and Ittmann M.

ADDITIONAL INFORMATION

• Full Name: FGF9 ELISA Kit (Fibroblast Growth Factor-9)
• Reactivity: Human
• Sample Type: Plasma, Biological Fluids, Serum, Tissue Homogenates
• Sensitivity: 37.5 pg/ml

OTHER RELATED ELISA KITS

• CD105 (Endoglin) ELISA Kit
• TGF Alpha ELISA Kit
• hGH ELISA Kit